Breast surgical oncologist Mediget Teshome was named chief of breast surgery and director of breast health at UCLA Health.
Jennifer Gillette was named the University of New Mexico Comprehensive Cancer Center’s associate director for training and education.
The University of Cincinnati Cancer Center’s Maria F. Czyzyk-Krzeska was awarded a five-year, $2.8 million grant from the NIH to investigate how copper contributes to the advancement and recurrence of the most common type of kidney cancer, clear cell renal cell carcinoma.
Jezabel Rodriguez Blanco, who has a dual appointment at MUSC Hollings Cancer Center and the Darby Children’s Research Institute at MUSC, will receive $800,000 over four years from Alex’s Lemonade Stand Foundation for Childhood Cancer to continue her pursuit of the causes of medulloblastoma relapse.
St. Jude Children’s Research Hospital invested nearly $13 million toward a research collaboration with scientists at Columbia University, Duke University, and Stanford University to expand the understanding of G-protein coupled receptors, which are vital proteins that impact human health and disease.
The Centers for Medicare & Medicaid Services issued its rule requiring federal health plans—including Medicare Advantage plans, Medicaid plans, and Qualified Health Plans on Federally Facilitated Exchanges—to establish an electronic prior authorization process that will be integrated into providers’ workflows.
The National Association for Proton Therapy commended CMS for ensuring seniors have timely access to medical care, especially advanced cancer treatments, through the Advancing Interoperability and Improving Prior Authorization Processes, or e-PA, Rule.
Doctors at the University of New Mexico Comprehensive Cancer Center successfully treated blood cancer patients using allogeneic stem cell transplant—a first for New Mexico.
A study led by researchers from the UCLA Health Jonsson Comprehensive Cancer Center showed that using high doses of radiation while integrating an ablative radiotherapy technique called stereotactic ablative radiotherapy concurrently with chemotherapy is safe and effective in treating people with locally advanced non-small cell lung cancer that is not suitable for surgery.
Scientists at University of California San Diego School of Medicine used a machine learning algorithm to predict when cancer will resist chemotherapy.
